It is well known that several important drug discoveries have been made by chance, the most famous being penicillin (1928), insulin (1923), cyclosporine (1973) and Viagra (1995) . In fact, the expression "by chance" is not really appropriate since the discovery of these drugs was incidental rather than accidental. It was really incidental because of the expertise of the so called discoverers rather than a lack of any related information, which would have been accidental. As mentioned by Pasteur, the most famous French scientist: "In the fields of observation, chance favors only the prepared minds". The discovery of these drugs themselves or the unexpected drug activity could be said to have been uncovered by serendipity. The word serendipity was coined in relation to a fable involving three princes of Serendip, an island now called Sri Lanka, involving an unusual camel. The origin of the word comes from a sanscript word serendipity meaning the golden island. The best example of genuine serendipity is the discovery by Christopher Colombus of America in 1492, when he was looking for a new way to go to India and landed into America; native Americans were therefore called Indians. Among the drugs in thrombosis and haemostasis, we believe that heparin, the antiplatelet activity of aspirin and, more recently, previously unknown thalidomid antineoplastic activity were discovered by serendipity. These examples illustrate the role of serendipity in medical progress in drug therapy saving a multitude of lives worldwide. In this presentation, we will discuss the serendipity involved in these three medications.
New targets in cardiovascular prevention: the identification of specific disease mechanisms
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Heart Care Foundation ONLUS, Florence, Italy Correspondence: Via A. Lamarmora 36, Florence, Italy. amaseri@heartcarefound.org The established efficacy of available preventive treatments reduces the possibility of further significant reductions of risk using newly discovered treatments against the same targets. As a consequence, clinical trials need to enroll larger and larger numbers of patients in order to detect statistically significant reductions of adverse events, but the practical improvement in clinical outcome in absolute terms, is progressively getting smaller. Therefore, novel research strategies should be explored in order to identify novel, more specific therapeutic targets. Understanding of etiologic mechanisms is a key component of effective prevention. Consider the treatment of anemia as an example. Identification of etiologic factors is mandatory to prevent recurrences (e.g., iron deficiency from insufficient intake, malabsorption or excessive loss), and preventive treatment varies according to the causal mechanism (The prospect of a polipill would be unconceivable for hematologists!).
Innovative clinical cardiovascular research approaches should focus on the outliers rather than merely on patients with typical, average presentation, evolution and response. In those subsets of patients who deviate most from the average behavior, the identification of distinctive features could provide clues of novel, specific pathogenic components which could suggest new therapeutic targets.
